Introduction
============

Oral squamous cell carcinoma (OSCC) is the most common malignancy of head and neck. [@B1]. The mortality rates of OSCC are still high despite progress of treatment and diagnosis in the past decades [@B2]. It is urgently required to uncover the mechanisms of initiation and development of OSCC. It has been demonstrated that dysregulated alternative splicing of pre-mRNA is associated with OSCC [@B3], [@B4]. Several splicing factors have been shown to be involved in the tumorigenesis of OSCC [@B5], [@B6].

SR proteins (serine/arginine-rich proteins), functioning as messenger-RNA-binding proteins and alternative splicing factors, all contain one or two RNA recognition motif(s) (RRM) and a protein-interaction arginine-serine rich (RS) domain [@B7]. SRSF3 (serine/arginine-rich splicing factor 3), also known as SRp20 or SFRS3, is the smallest member of SR proteins [@B8]. SRSF3 is a multi-functional protein. It has been shown to be involved in multiple cellular functions, such as alternative splicing [@B9], [@B10], DNA repair [@B11], RNA export [@B12], [@B13], alternative RNA polyadenylation [@B14], and protein translation [@B15], [@B16]. SRSF3 has been found to be involved in a number of human diseases, including cancer [@B17]. It has been demonstrated to be a proto-oncogene and often overexpressed in multiple cancers, including OSCC [@B18], [@B19]. However, the relationship between SRSF3 and carcinogenesis and caner progression remains unclear.

In this study, we analyzed the expression of SRSF3 in oral precancerous and cancerous tissues. We found that SRSF3 is overexpressed in oral cancer and moderate or severe dysplasia tissues. Patients with high grade cancer or lymphatic metastasis showed up-regulated expression of SRSF3.

Materials and Methods
=====================

Cells and RNAi
--------------

FaDu cells (ATCC) were cultured in Dulbecco\'s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS; HyClone, USA) and 1% antibiotic-antimycotic (Invitrogen, USA). SRSF3 siRNA\#1 and \#2 were purchased from Santa Cruz Biotechnology and Ambion, respectively. FaDu cells were transfected with 20nM siRNA in the presence of Lipofentamine 2000 (Invitrogen, USA) according to the manufacturer\'s instructions. After 48h, cells were passed and received another transfection. After 96h, total proteins were collected by adding 2× sodium dodecyl sulfate sample buffer, and boiled for 5 min. Total RNAs were purified by TRIzol reagent (Invitrogen, USA).

Patients and Tissue Samples
---------------------------

Seventy-seven patients diagnosed as oral squamous cell carcinoma and eleven patients diagnosed as epithelial dysplasia were involved in this study. All histologic diagnoses were performed by the pathology department in the School and Hospital of Stomatology, Wuhan University. Normal oral mucosal tissues were obtained from non-tumor adjacent tissues or patients with reshaping of gingival tissues. Informed consent was obtained from all subjects. All experimental protocols were approved by the Ethics Committee at the School and Hospital of Stomatology in Wuhan University.

Immunohistochemistry
--------------------

Immunohistochemical staining was performed using mouse anti-SRSF3 monoclonal antibody (Invitrogen, USA) and the avidin-biotin peroxidase complex method with a Vectastain ABC kit (Vector Laboratories, USA). In brief, tissue sections were deparaffinized with xylene and rehydrated through grade alcohols, followed by antigen retrieval in 0.01 M sodium citrate buffer (pH 6.0) and quenching of endogenous peroxidase activity with 3% H~2~O~2~. Then, sections were blocked with normal horse serum solution, followed by incubation with anti-SRSF3 primary antibody, biotinalyed anti-mouse IgG, and avidin-biotin peroxidase complex (ABC). Specific staining of SRSF3 was developed by DAB (Vector Laboratories Inc., USA).

SRSF3 specific staining was quantified by using imageJ software [@B20]. A mean staining value from three representative regions of each sample was calculated. SRSF3 specific staining score was divided to 4 levels (0-3) based on staining value (0: staining value \<10, 1: staining value10-15, 2: staining value 15-20, 3: staining value \>20).

Oncomine cancer microarray database analyses
--------------------------------------------

Oncomine is an online cancer microarray database [@B21]. There were nine analyses of oral squamous cell carcinoma *vs* normal control samples, and one salivary gland cancer *vs* normal control until Oct 30, 2015. A meta-analysis was used to compare the expression levels of SRSF3 between cancer and normal samples.

DMBA treatment in normal epithelial cells
-----------------------------------------

Normal gingival epithelial cells (N1 and N2) were collected from gingival tissues and grown in keratinocyte growth medium (KGM, Lonza, Switzerland). N2 cells were counted. The same number cells were treated with 5 µg/ml 7, 12-Dimethylbenz\[a\]anthracene (DMBA) (Sigma-Aldrich, USA) or DMSO (Dimethyl sulfoxide) for two days, and then total proteins were collected with 2× sodium dodecyl sulfate sample buffer.

Western Blot Analysis
---------------------

Protein samples were separated in 10% SDS-PAGE gel and transferred to a nitrocellulose membrane. The blot was incubated with the following antibodies: mouse monoclonal antibodies against SRSF3 (1:100 dilution, Invitrogen, USA), beta-actin (1:1000 dilution, Sigma-Aldrich, USA), and GAPDH (1:1000, Abmart, China).

Real-time quantitative RT-PCR (qRT-PCR)
---------------------------------------

Total RNA was treated with DNase I (Invitrogen), and then reverse-transcribed using random hexamers at 37°C with the M-MLV reverse transcriptase (Promega, Madison, USA). Real-time quantitative RT-PCR was performed using SYBR Green (GeneCopoeia, USA) in a Real-time PCR machine (QuantStudio 6 Flex System, Applied Biosystems, Foster City, CA). Primers for qRT-PCR are synthesized based on the publication [@B22], except N-cadherin forward primer (5\' CCACCTACAAAGGCAGAAGAGA 3\'). GAPDH was used as a reference and amplified with following primer pairs: 5\'GAAGGTGAAGGTCGGAGTC 3\' and 5\' GAAGATGGTGATGGGATTTC 3\'. The relative levels of gene expression were calculated as ΔCt = Ct(gene) - Ct(reference). The 2^-ΔΔ^Ct method was used to calculate the fold-change of gene expression.

Statistical Analyses
--------------------

The scores of SRSF3 were compared between groups using the nonparametric Mann-Whitney *U*-test or Kruskal-Wallis test in SPSS software. *p*\<0.05 was considered statistically significant. For real-time qRT-PCR, two group statistical comparisons of means were calculated with student\'s *t*-test.

Results
=======

The expression of SRSF3 in OSCC and Dysplasia
---------------------------------------------

SRSF3 has been shown to be overexpressed in multiple cancers [@B18]. To understand the potential role of SRSF3 in OSCC, firstly, we compared the expression levels of SRSF3 in normal oral mucosal, dysplasia, and OSCC tissues. We found that SRSF3 is significantly differently expressed in normal, precancerous (dysplasia) and cancerous tissues (*p*\<0.05, Table [1](#T1){ref-type="table"}). Cancerous tissues showed significantly higher levels of SRSF3 than normal tissues (*p\<*0.01). Next, we tried to correlated SRSF3 expression levels with the grading of oral epithelial dysplasia. In the early stage of dysplasia (mild stage), there is no significant increased expression of SRSF3. When progressing to moderate or severe dysplasia, lesion tissues showed significantly higher levels of SRSF3 than normal tissues (*p*\<0.01, Table [2](#T2){ref-type="table"}, Figure [1](#F1){ref-type="fig"}A-C). Moreover, we tried to correlate SRSF3 expression levels with the grading of OSCC. We found that SRSF3 is significantly differently expressed in different grades of OSCC (*p*\<0.05, Table [3](#T3){ref-type="table"}, Figure [1](#F1){ref-type="fig"}D-F). OSCCs with higher grade tend to have higher levels of SRSF3.

We also used Oncomine microarray database to analyze the expression level of SRSF3 in other studies of oral cancer. A meta-analysis combined nine analyses of oral squamous cell carcinoma *vs* normal control samples showed significantly higher expression of SRSF3 level in cancer than normal tissues (*p*\<0.001, Figure [S1](#SM1){ref-type="supplementary-material"}A). A study of salivary gland cancer *vs* normal control also showed significantly overexpressed SRSF3 in cancer (Figure [S1](#SM1){ref-type="supplementary-material"}B). These results suggested that SRSF3 is associated with carcinogenesis and progression of oral squamous cell carcinoma.

SRSF3 expression is associated with clinicopathologic characteristics of OSCC patients
--------------------------------------------------------------------------------------

Metastasis is one of the major factors causing the death of cancer. We found that patients with lymphatic metastasis showed significantly higher SRSF3 expression than those without lymphatic metastasis (*p*=0.038) (Table [3](#T3){ref-type="table"}, Figure [2](#F2){ref-type="fig"}). This result suggested that SRSF3 might be also involved in metastasis.

Epithelial-mesenchymal transition (EMT) has been proposed to initiate the metastasis of cancer cells [@B23], [@B24]. We investigated the effect of SRSF3 on the expression of EMT related-genes. We knocked down SRSF3 in FaDu cells (a head and neck cancer cell line with metastasis characteristics) with two siRNAs targeting different regions of SRSF3 mRNA (Figure [3](#F3){ref-type="fig"}B). The expression levels of Slug and N-cadherin significantly decreased after SRSF3 knockdown (Figure [3](#F3){ref-type="fig"}A). No significantly changes were found in the expression levels of VIM, Snail1, Twist, and E-cadherin. These results indicated that SRSF3 might participate metastasis *via* regulating the expression of Slug and N-cadherin.

Smoking and drinking are general risk factors of carcinogenesis. We found that there is no significant difference in the expression of SRSF3 level between smoking and non-smoking or between drinking and non-drinking patients (Table [3](#T3){ref-type="table"}). SRSF3 may be a relative independent factor during carcinogenesis. In addition, there was no correlation between SRSF3 and age or sex of patients (Table [3](#T3){ref-type="table"}).

Carcinogen increased the expression of SRSF3
--------------------------------------------

SRSF3 is up-regulated in moderate or severe dysplasia tissues. Many carcinogens are capable to induce dysplasia. Therefore, we analyzed the effect of carcinogen DMBA on the expression of SRSF3. Primary cultured oral epithelial cells had much lower level of SRSF3 than CAL 27 cells (an oral cancer cell line) (Figure [4](#F4){ref-type="fig"}). When primary cultured oral epithelial cells were exposed to DMBA for two days, SRSF3 expression level significantly increased. This result suggested that carcinogen might be the cause of overexpression of SRSF3.

Discussion
==========

Oral squamous cell carcinoma, encompassing more than 90% of oral tumors, counts among the most frequent malignancies of head and neck [@B1]. Five-year relative survival rate (%) of oral cancer patients, diagnosed between 2003 and 2009, is 65%, which is much lower than those of breast cancer patients and prostate cancer patients [@B2]. An important reason for poor treatment outcome of OSCC is the poor understanding of its tumorigenesis. OSCC is associated with aberrant alternative splicing of pre-mRNA due to overexpression of splicing factor hnRNP A1 [@B6]. Here, we focused on another key splicing factor, SRSF3, and expanded our knowledge of how splicing factor is associated with OSCC.

Previous studies showed that SRSF3 is overexpressed in cancers of the cervix and ovary [@B18], [@B25]. Recently, in consistent with previous studies, we found that SRSF3 is overexpressed in OSCC cells [@B19]. Here, we also found that SRSF3 was overexpressed in OSCC tissues based on a meta-analysis of oral cancer researches in Onocmine microarray database. In this study, we further investigated the relationship between SRSF3 expression and clinical characteristics of OSCC patients. Because most of our samples are formalin-fixed, paraffin-embedded tissues, we only performed immunohistochemistry to analyze the expression of SRSF3 in patients instead of qRT-PCR or Western blot. We found that SRSF3 is up-regulated in moderate or severe dysplasia tissues compared with normal oral mucosal epithelial tissues, and higher grade cancers express more SRSF3. Our data clearly showed gradually increased expression of SRSF3 is associated with the development of precancerous lesions and cancer. SRSF3 may be a new potential molecular marker for OSCC.

Overexpression of SRSF3 in an immortalized mouse embryonic fibroblast has been demonstrated to be able to initiate tumor formation [@B18]. We found that carcinogen DMBA significantly increased the expression of SRSF3 in normal oral primary epithelial cells. In addition, moderate or severe dysplasia tissues showed significantly higher SRSF3 than normal tissues. These results are correlated with previous study and strongly suggest that SRSF3 may be involved in the initiation of OSCC and be a therapeutic target for the prevention of OSCC.

Metastasis is the major cause of cancer related mortality [@B26]. Splicing factor SRSF1 has been reported to enhance metastasis by promoting the expression of ΔRon isoform of Ron tyrosine kinase receptor [@B27]. Here, we proposed that SRSF3 is associated with metastasis based on two evidences: first, patients with lymphatic metastasis showed significantly higher SRSF3 expression than those without lymphatic metastasis; second, knockdown of SRSF3 significantly reduced the expression of two EMT-related genes, Slug and N-cadherin. Slug represses the expression of E-cadherin [@B28]. However, we did not observe the increase of E-cadherin upon SRSF3 knockdown. This may be because that the expression of E-cadherin is also repressed by Snail [@B29]. In the present study, we found that one anti-SRSF3 siRNA has no effect on Snail, whereas another anti-SRSF3 siRNA increased the expression of Snail. Therefore, SRSF3 only regulates the expression of Slug.

N-cadherin has been shown to be associated with anti-apoptotic signaling pathways [@B30]. Its transcription is activated by Twist [@B31]. Our results showed decrease of N-cadherin and no change in Twist upon SRSF3 knockdown. This may suggest that SRSF3 regulates the expression of N-cadherin *via* Twist-independent pathway.

Alternative splicing has been increasingly associated with cancers [@B32]. SR splicing factor family (such as SRSF3 [@B18] and SRSF1 [@B33]) and SR-related proteins (such as Tra2β) [@B34] have been concluded to be oncogene or closely associated with oncogenesis. However, the relationship between these splicing factors and carcinogenesis and caner progression remains largely unclear. In the present study, we provided more evidences about how SRSF3 is correlated with progression of OSCC. Further studies may focus on the therapeutic strategies targeting SRSF3 in cancers.

Conclusions
===========

In conclusion, we found that SRSF3 is overexpressed in OSCC tissues and associated with the initiation and development of precancerous lesions and cancer. SRSF3 may be a biomarker and therapeutic target of OSCC.
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![Expression of SRSF3 in oral epithelial dysplasia and cancers. Expression of SRSF3 was analyzed with immunohistochemistry in normal (**A**), mild dysplasia (**B**), severe dysplasia (**C**), grade I OSCC (**D**), grade I-II OSCC (**E**), or grade II-III OSCC tissues (**F**). (**A-F**: magnification ×40).](ijmsv13p0533g001){#F1}

![Expression of SRSF3 is associated with lymphatic metastasis of OSCC. Expression of SRSF3 was analyzed with immunohistochemistry in OSCC patients with or without lymphatic metastasis (magnification ×40).](ijmsv13p0533g002){#F2}

![SRSF3 regulates the expression of epithelial-mesenchymal transition (EMT) related-genes. FaDu cells were treated with siRNA twice in an interval of 48 hours. (A) The expression of E-cadherin (E-cad), Slug, Twist, Snail and Vimentin (VIM) was analyzed by real-time quantitative RT-PCR. GAPDH served as the reference. (B) Western blot showed knockdown efficiency of SRSF3 in FaDu cells. GAPDH served as loading control.](ijmsv13p0533g003){#F3}

![Carcinogen increased the expression of SRSF3. (**A**) Expression of SRSF3 in primary cultured oral epithelial cells (N1 and N2) and CAL 27 (an oral cancer cell line) was analyzed with western blot. (**B**) Primary cultured oral epithelial cells (N2) were treated with DMBA (5 µg/ml) for two days. DMSO treatment was used as control. Western blot was used to analyze the expression of SRSF3. β-actin served as loading control.](ijmsv13p0533g004){#F4}

###### 

Expression of SRSF3 in normal, dysplasia, or OSCC tissues.

  Histopathological Classification   Case number (%)   SRSF3 staining   *p*-value            
  ---------------------------------- ----------------- ---------------- ----------- ---- --- -------
  Normal oral mucosa                 14 (13.7%)        10               3           1    0   0.012
  Dysplasia                          11 (10.8%)        3                5           2    1   
  OSCC                               77 (75.5%)        24               25          20   8   

###### 

Correlation of SRSF3 expression with the grading of oral epithelia dysplasia.

  Classification       Case number (%)   SRSF3 staining   *p*-value                      
  -------------------- ----------------- ---------------- ----------- --- --- ---------- ---------
  Normal oral mucosa   14 (13.7%)        10               3           1   0              
  Dysplasia            Mild              5 (45.5%)        3           1   1   0          0.53^a^
  Moderate to severe   6 (54.5%)         0                4           1   1   0.006^b^   
  Sex (dysplasia)      Male              6 (54.5%)        1           2   2   1          0.121
  Female               5 (45.5%)         2                3           0   0              
  Age (displasia)      ≤55               4 (36.4%)        1           2   1   0          0.927
  \>55                 7 (63.6%)         2                3           1   1              

a, Normal *vs* mild dysplasia, b, Normal *vs* moderate to severe dysplasia.

###### 

Correlation of SRSF3 expression with clinicopathologic characteristics of OSCC patients.

  Classification         Case number (%)   SRSF3 staining   *p*-value                 
  ---------------------- ----------------- ---------------- ----------- ---- ---- --- -------
  Tumor grade            I                 12 (15.6%)       8           3    1    0   0.016
  I-II & II              49 (63.6%)        11               18          16   4        
  II-III & III           16 (20.8%)        5                5           2    4        
  Lymphatic metastasis   Positive          38 (49.3%)       10          8    15   5   0.038
  Negative               39 (50.7%)        16               14          5    4        
  Gender                 Male              58 (75.3%)       17          19   13   9   0.550
                         Female            19 (24.7%)       6           7    5    1   
  Age                    ≤55               38 (49.4%)       13          14   6    5   0.298
  \>55                   39 (50.6%)        11               10          13   5        
  Tobacco Smoking        Positive          41 (53.2%)       11          15   9    6   0.59
  Negative               36 (46.8%)        13               9           11   3        
  Drinking               Positive          34 (44.2%)       7           12   10   5   0.110
                         Negative          43 (55.8%)       17          12   10   4   
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